Zubeyer Hossain Jacky ID: 121-14-678 Section : A MBA Program, spring, 2013 MGT: 501, Strategic Management Faculty

of Business & Economics Daffodil International University Dhaka, Bangladesh.

Nepal. Qatar. Sri Lanka. Iran. Mexico. England.Bhutan. Ghana. Russia. SQUARE Pharmaceuticals Limited is the largest pharmaceutical company in Bangladesh and it has been continuously in the 1st position among all national and multinational companies since 1985. Yemen.SQUARE Pharmaceuticals Limited has extended the range of services towards the highway of global market. The current yearly group turnover is 616 million USD. Present markets . Kenya. Costa Rica.Philippines. Denmark. Sierra Leone. Singapore. Vietnam. It was established in 1958 and converted into a public limited company in 1991. Saudi Arabia. Cambodia. Thailand . Mozambique. Libya. Hong Kong. Markets under exploration . Myanmar. . Papua New Guinea. Laos. Somalia. Iraq.Business level strategies and their impacts on the performance of an Enterprise : A Case Study of Square pharmaceuticals Ltd. Uzbekistan.

Opportunities a. low staff morale or diseconomies of scale. b. Weaknesses a. SPL’s weakness could include poor branding. SPL has well developed chemistry. R&D efforts of Bangladeshi pharmaceutical companies are hampered by lack of enabling regulatory requirement. . SPL also has a strong marketing & distribution network. Due to the cost advantage in contract manufacturing & Research multi-national companies find it compelling to shift their production bases to countries offering such cost advantage. Export effort is hampered by procedural hurdles in Bangladesh as well as non-tariff barriers imposed abroad.Strengths a. b. b. Threats a. Marketing alliances for MNC products in domestic and international market is another emerging opportunity. c. b. R&D and manufacturing infrastructure. Low investments in innovative R&D and Inadequate manufacturing practices. Square maintains high quality standards for its products.